{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-040429","form_type":"8-K","ticker":null,"cik":"0001840904","company_name":"ATAI Life Sciences N.V.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.753639+00:00","generated_at":"2026-05-17T00:24:09.605914+00:00","sec_items":["2.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Atai Beckley completes acquisition of Beckley Psytech, creating AtaiBeckley; issues ~105M shares","bullets":["Consideration of ~105M new shares issued to Beckley Psytech shareholders, representing ~28% of combined company.","Combined cash expected to fund operations into 2029, through first Phase 3 trial of BPL-003 for TRD.","BPL-003 (mebufotenin benzoate nasal spray) is Phase 3-ready; End-of-Phase 2 FDA meeting scheduled, Phase 3 start Q2 2026.","Board: Christian Angermayer (Chairman), Scott Braunstein (Vice Chairman), Cosmo Feilding Mellen, Robert Hershberg.","Shareholders approved redomiciliation to Delaware; expected completion around year-end 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-040429","json":"https://secwatch.observer/filing/0001140361-25-040429.json","markdown":"https://secwatch.observer/filing/0001140361-25-040429.md","text":"https://secwatch.observer/filing/0001140361-25-040429.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125040429/0001140361-25-040429-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125040429/ef20058318_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:24:09.605914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"368638c820dfb9f7be3b5a3394de87fda4729205","claim":"ATAI Life Sciences N.V. completed an acquisition involving shareholders of Beckley Psytech for 103,000,066 ordinary shares in atai’s capital (closed 2025-11-05).","evidence_excerpt":"Agreement”). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066 ordinary shares in atai’s capital (“Ordinary Shares”) issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement, which such","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125040429/0001140361-25-040429-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-063775","ticker":"ESAB","company_name":"ESAB Corp","filed_at":"2026-06-02T10:41:21+00:00","headline":"ESAB completes $1.45B acquisition of Eddyfi Technologies","event_type":"m_and_a","sec_items":["2.01","3.02","5.03","3.03","7.01","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: ma_transaction","same SEC item: 2.01, 3.02, 7.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063775","json":"https://secwatch.observer/filing/0001213900-26-063775.json","markdown":"https://secwatch.observer/filing/0001213900-26-063775.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1877322/000121390026063775/0001213900-26-063775-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1877322/000121390026063775/ea0292710-8k_esab.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"Agreement”). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066\n ordinary shares in atai’s capital (“Ordinary Shares”) issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement, which such","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125040429/0001140361-25-040429-index.htm","comparable_excerpt":"Québec and a wholly owned indirect subsidiary of the Company (the “ Purchaser ”), acquired\nall of the issued and outstanding shares of Eddyfi from the vendors for cash equal to $1.45 billion, subject to customary purchase price\nadjustments set forth in the Purchase Agreement relating to cash, indebtedness, transaction expenses, and net working capital of Eddyfi,\nits","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1877322/000121390026063775/0001213900-26-063775-index.htm"}},{"accession":"0001628280-26-032558","ticker":"APAD","company_name":"Enhanced Group Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Enhanced Group completes de-SPAC merger with Enhanced Ltd; redemptions of $201.7M","event_type":"m_and_a","sec_items":["1.01","2.01","5.06","3.02","9.01","4.01","3.01","3.03","5.01","5.02","5.03","5.05","7.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: ma_transaction","same SEC item: 2.01, 3.02, 7.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-032558","json":"https://secwatch.observer/filing/0001628280-26-032558.json","markdown":"https://secwatch.observer/filing/0001628280-26-032558.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1956439/000162828026032558/0001628280-26-032558-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1956439/000162828026032558/apadu-20260506.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"Agreement”). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066\n ordinary shares in atai’s capital (“Ordinary Shares”) issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement, which such","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125040429/0001140361-25-040429-index.htm","comparable_excerpt":"On May 7, 2026, as contemplated by the Business Combination Agreement and as described in the section titled “ The BCA Proposal ” beginning on pa ge 180 of the Proxy Statement/Prospectus, the Company, Enhanced and Merger Sub consummated the business combination contemplated by the Business Combination Agreement, whereby: • Merger Sub merged with and into Enhanced (the “First Merger”), with Enhanced surviving the merger as a wholly owned subsidiary of the Company;","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1956439/000162828026032558/0001628280-26-032558-index.htm"}},{"accession":"0001104659-26-057182","ticker":"RMIX","company_name":"Suncrete, Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Suncrete acquires Nelson Bros. Ready Mix for $42.3M cash + stock; earnout up to $18M","event_type":"m_and_a","sec_items":["1.01","2.01","3.02","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: ma_transaction","same SEC item: 2.01, 3.02, 7.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057182","json":"https://secwatch.observer/filing/0001104659-26-057182.json","markdown":"https://secwatch.observer/filing/0001104659-26-057182.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2094433/000110465926057182/0001104659-26-057182-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2094433/000110465926057182/tm2613866d1_8k.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"Agreement”). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066\n ordinary shares in atai’s capital (“Ordinary Shares”) issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement, which such","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125040429/0001140361-25-040429-index.htm","comparable_excerpt":"Mr. Owens, Ms. Owens and JAO, the “Sellers”),\nand Jacob Owens in his capacity as representative of the Sellers. The aggregate consideration\nfor the Acquisition consisted of (i) 1,296,456 shares of Class A Common Stock, par value $0.0001 per share, of the Company (“Class\nA Common Stock”) issued to the Sellers (the “Stock Consideration”) and (ii) a $42.3 million net","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2094433/000110465926057182/0001104659-26-057182-index.htm"}},{"accession":"0001140361-26-018716","ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-05-04T23:59:59+00:00","headline":"Gyre Therapeutics completes $300M all-stock acquisition of Cullgen; appoints Ying Luo as CEO","event_type":"m_and_a","sec_items":["2.01","5.03","1.01","3.02","3.03","5.02","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: ma_transaction","same SEC item: 2.01, 3.02, 7.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-018716","json":"https://secwatch.observer/filing/0001140361-26-018716.json","markdown":"https://secwatch.observer/filing/0001140361-26-018716.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/0001140361-26-018716-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/ef20072211_8k.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"Agreement”). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066\n ordinary shares in atai’s capital (“Ordinary Shares”) issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement, which such","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125040429/0001140361-25-040429-index.htm","comparable_excerpt":"Revenue Code of 1986, as\n amended. Under the terms of the Merger Agreement, the Company acquired Cullgen in an all-stock transaction that valued Cullgen at\n approximately $300 million. At the effective time of the Merger (the “Effective Time”), each then outstanding share of Cullgen capital stock (the “Cullgen Capital Stock”), excluding shares of Cullgen","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/0001140361-26-018716-index.htm"}},{"accession":"0001193125-26-197835","ticker":"BKKT","company_name":"Bakkt, Inc.","filed_at":"2026-04-30T23:59:59+00:00","headline":"Bakkt completes acquisition of DTR; issues ~11.3M shares to sellers including CEO","event_type":"m_and_a","sec_items":["2.01","1.01","3.02","5.01","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: ma_transaction","same SEC item: 2.01, 3.02, 7.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-197835","json":"https://secwatch.observer/filing/0001193125-26-197835.json","markdown":"https://secwatch.observer/filing/0001193125-26-197835.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1820302/000119312526197835/0001193125-26-197835-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1820302/000119312526197835/d233784d8k.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"Agreement”). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066\n ordinary shares in atai’s capital (“Ordinary Shares”) issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement, which such","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125040429/0001140361-25-040429-index.htm","comparable_excerpt":"Purchase Agreement) for purposes of consummating the acquisition of DTR at Closing. At the closing of the acquisition of DTR (the “Closing”), the Company issued an aggregate of 11,316,775 shares (such shares, the “Consideration Shares”) of its Class A Common Stock, par value $0.0001 per share (the “Class A Common Stock”), comprised of (A) 31.5% of (i) the aggregate","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1820302/000119312526197835/0001193125-26-197835-index.htm"}},{"accession":"0001104659-26-050956","ticker":"RMIX","company_name":"Suncrete, Inc.","filed_at":"2026-04-29T23:59:59+00:00","headline":"Suncrete completes acquisition of Hope Concrete (10 plants, 88 trucks) for $39.4M + equity","event_type":"m_and_a","sec_items":["1.01","2.01","3.02","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: ma_transaction","same SEC item: 2.01, 3.02, 7.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-050956","json":"https://secwatch.observer/filing/0001104659-26-050956.json","markdown":"https://secwatch.observer/filing/0001104659-26-050956.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2094433/000110465926050956/0001104659-26-050956-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2094433/000110465926050956/tm2613031d1_8k.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"Agreement”). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066\n ordinary shares in atai’s capital (“Ordinary Shares”) issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement, which such","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125040429/0001140361-25-040429-index.htm","comparable_excerpt":"in its capacity as representative of the Sellers. After giving effect to the\ntransactions contemplated by the Purchase Agreement, the aggregate consideration consisted of (i) 220,007 shares (the “Mikytuck\nRollover Securities”) of Class A Common Stock, par value $0.0001 per share, of the Company (“Class A Common Stock”)\nissued to Mr. Mikytuck, (ii) 69,511","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2094433/000110465926050956/0001104659-26-050956-index.htm"}},{"accession":"0001437749-26-012942","ticker":"LSF","company_name":"Laird Superfood, Inc.","filed_at":"2026-04-21T23:59:59+00:00","headline":"Laird Superfood acquires Terrasoul for $48M cash plus $5M earnout; Nexus invests $60M in preferred stock","event_type":"m_and_a","sec_items":["1.01","2.01","3.02","5.02","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: ma_transaction","same SEC item: 2.01, 3.02, 7.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-012942","json":"https://secwatch.observer/filing/0001437749-26-012942.json","markdown":"https://secwatch.observer/filing/0001437749-26-012942.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650696/000143774926012942/0001437749-26-012942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650696/000143774926012942/lsf20260421_8k.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"Agreement”). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066\n ordinary shares in atai’s capital (“Ordinary Shares”) issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement, which such","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125040429/0001140361-25-040429-index.htm","comparable_excerpt":"Interests (as defined in the Terrasoul Acquisition Agreement) which constitute all of the issued and outstanding equity interests of Terrasoul, for a purchase price of (i) $48.0 million in cash, subject to customary purchase price adjustments, including adjustments for working capital, cash, debt and transaction expenses and (ii) potential earnout consideration","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1650696/000143774926012942/0001437749-26-012942-index.htm"}},{"accession":"0001213900-26-042811","ticker":"PHGE","company_name":"BiomX Inc.","filed_at":"2026-04-13T23:59:59+00:00","headline":"BiomX accelerates option exercise, acquires 60% stake in DFSL for $750k cash, $3M note","event_type":"m_and_a","sec_items":["1.01","2.01","3.02","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: ma_transaction","same SEC item: 2.01, 3.02, 7.01, 9.01","same event type: m_and_a","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-042811","json":"https://secwatch.observer/filing/0001213900-26-042811.json","markdown":"https://secwatch.observer/filing/0001213900-26-042811.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739174/000121390026042811/0001213900-26-042811-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739174/000121390026042811/ea0285293-8k_biomx.htm"},"side_by_side_evidence":{"fact_type":"ma_transaction","source_excerpt":"Agreement”). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066\n ordinary shares in atai’s capital (“Ordinary Shares”) issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement, which such","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125040429/0001140361-25-040429-index.htm","comparable_excerpt":"delivery. In consideration for the Purchased Shares, the\nCompany agreed to the following consideration to Mandragola: (i) a cash payment of Seven Hundred Fifty Thousand Dollars ($750,000),\nof which Four Hundred Fifty Thousand ($450,000) was advanced by the Company; (ii) the issuance of an unsecured convertible promissory note in the principal\namount of Three","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1739174/000121390026042811/0001213900-26-042811-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}